Teva Pharmaceutical Industries Ltd (ADR) Stock Nasdaq
Stocks
US8816242098
Pharmaceuticals
OTC Markets Traded| Market Cap | 43.03B 36.88B 34.5B 31.54B 59.52B 4,121B 60.16B 408B 159B 2,069B 162B 158B 6,846B | P/E 2026 * |
49.5x | P/E 2027 * | 20.3x |
|---|---|---|---|---|---|
| Enterprise Value | 54.91B 47.06B 44.02B 40.25B 75.95B 5,258B 76.76B 521B 203B 2,640B 206B 202B 8,736B | EV / Sales 2026 * |
3.31x | EV / Sales 2027 * | 2.98x |
| Free-Float |
88.59% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Ltd (ADR)
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 01/01/2023 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 22/12/2019 |
Matthew Shields
COO | Chief Operating Officer | 52 | 03/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 01/01/2009 |
Sol Barer
CHM | Chairman | 78 | 06/02/2017 |
Rosemary Crane
BRD | Director/Board Member | 65 | 01/09/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 43.03B | |
| -0.67% | +5.39% | +75.21% | +127.54% | 1,111B | |
| +1.04% | +4.07% | +52.29% | +65.39% | 658B | |
| -0.17% | +5.67% | +25.60% | +80.40% | 467B | |
| +0.13% | +4.02% | +41.64% | +42.38% | 369B | |
| +0.26% | +2.72% | +24.32% | +41.06% | 301B | |
| +0.62% | +4.76% | +1.19% | +12.65% | 256B | |
| +1.03% | +5.83% | +51.11% | +72.96% | 240B | |
| +2.51% | +2.34% | -17.77% | -53.66% | 207B | |
| +0.42% | +5.63% | +27.86% | +92.24% | 182B | |
| Average | +0.51% | +4.49% | +31.27% | +53.44% | 421.22B | |
| Weighted average by Cap. | +0.25% | +4.68% | +43.95% | +73.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.58B 14.21B 13.29B 12.15B 22.94B 1,588B 23.18B 157B 61.17B 797B 62.26B 60.91B 2,638B | 17.3B 14.83B 13.87B 12.68B 23.94B 1,657B 24.19B 164B 63.83B 832B 64.97B 63.57B 2,753B |
| Net income | 1.14B 977M 914M 836M 1.58B 109B 1.59B 10.82B 4.21B 54.83B 4.28B 4.19B 181B | 2.34B 2B 1.87B 1.71B 3.23B 224B 3.27B 22.17B 8.62B 112B 8.77B 8.58B 372B |
| Net Debt | 11.88B 10.18B 9.52B 8.71B 16.43B 1,137B 16.6B 113B 43.81B 571B 44.6B 43.63B 1,890B | 8.61B 7.38B 6.9B 6.31B 11.91B 825B 12.04B 81.69B 31.76B 414B 32.33B 31.63B 1,370B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
